Abstract. There has been a rapidly increasing interest in developing new therapies for management of atrial fibrillation. The optimal method for evaluating their efficacy is by measuring changes in outcomes such as mortality, quality of life or cost of care; requiring trials of large sample size. In order to reduce the sample size, there is a need to develop appropriate surrogate endpoints. "Is time to first recurrence of symptomatic atrial fibrillation" an appropriate surrogate endpoint for quality of life? Since a surrogate endpoint must capture the net effect of the treatment, it was assumed (a) that frequency of symptomatic episodes captures the net effect on quality of life and (b) "time to first recurrence" is a measure of the frequency of symptomatic episodes. The effect of frequency of symptomatic episodes or their duration and symptom severity on quality of life has not been evaluated. "Time to first symptomatic recurrence" was proposed because data from a few patients demonstrated that symptomatic atrial fibrillation episodes arose independently and randomly and could be represented mathematically by a Poisson distribution. Recent data from a greater number of patients with implantable devices that detect symptomatic and asymptomatic episodes of atrial tachyarrhythmias indicate that these episodes tend to cluster in time and cannot be well represented by a Poisson distribution. Because all atrial tachyarrhythmia episodes do not follow a Poisson distribution, it is unlikely that only symptomatic episodes would follow the same distribution, although this needs to be proved. A non-Poisson distribution requires a larger sample to detect differences in clinical trials. This should be taken into consideration when designing prospective trials. Alternative methods may include measuring frequency of symptomatic episodes as well their severity and duration. In patients with implanted devices, total duration of time spent in atrial tachyarrhythmias or objective measures of rate control should also be evaluated as surrogate endpoints. If surrogate endpoints cannot be developed, changes in clinical outcomes will need to be demonstrated to evaluate therapeutic efficacy.
Management of patients with atrial fibrillation is a significant challenge, which is being met with the development of new pharmacological and nonpharmacological therapies. In order to evaluate and compare therapeutic efficacy, objective criteria must be established. As clinical endpoints, one can utilize outcome measurements such as changes in mortality or cost of care but these outcomes typically require trials with large sample size and long follow-up duration. Since atrial fibrillation is associated with significant morbidity, one of the primary reasons for developing therapies for patients with atrial fibrillation is to improve their quality of life. Although objective measures of quality of life have been established, the effect of management of atrial fibrillation on a patient's overall quality of life may be small and trials with large sample size or long follow-up duration are also needed to demonstrate changes in this endpoint. To address this issue, there has been a significant interest in developing surrogate endpoints. A surrogate endpoint is a substitute for the clinically meaningful endpoint and changes induced by a therapy on a surrogate are expected to reflect changes in the clinically meaningful endpoint [1].
Time to First Episode
One endpoint that has been proposed is the "time to first symptomatic atrial fibrillation (AF) episode" [2] . For it to be a surrogate based on two assumptions: it is strongly correlated to the frequency of symptomatic AF episodes and a change in the frequency of symptomatic episodes capture the net effect of the treatment on changes in quality of life of the patient. Although it is reasonable to assume that a change in the frequency of symptomatic AF episodes may reflect a change in the overall quality of life, this has not been demonstrated in any studies. It is also possible that a patient's quality of life is not related to the frequency of symptomatic episodes but to the total duration and severity of symptoms during AF episodes i.e. symptomatic burden. Either hypothesis would need to be tested prospectively and will be discussed later.
The second assumption is that the time to first symptomatic recurrence is a valid representation of the frequency of the episodes. This was first proposed by Prichett et al. (2), and since then, several studies have questioned the validity of this assumption [3] [4] [5] . For this assumption to be valid, the symptomatic AF episodes must arise independently and randomly is such a manner that the occurrence of a symptomatic episode is not determined by when the previous episode occurred. The only mathematical model with this "memory-less" property is called the Poisson process, which has an exponential distribution. This is illustrated in Figure 1(a) where the inter-episode time intervals (i.e. termination of one episode to onset of next episode) of the first 16 symptomatic AF episodes in one patient are indicated. The inter-episode intervals are random and vary from 0.6 to 13.8 days. The cumulative proportion of AF episodes (Figure 1(b) ) indicate that in about 50% of the episodes, the inter-episode interval was within 5 days and in 100% within 15 days. This cumulative graph fits an exponential distribution of 1-e −0.24t , where the expected inter-episode time is the inverse of the exponent i.e. 1/0.24 which equals 4.2 days. For an exponential distribution, the same "expected" inter-episode time interval of 4.2 days could also be computed by taking a mean of the 16 inter-episode times. Therefore, in this patient, the inter-episode intervals follow a Poisson process. If the inter-episode intervals in all patients had this type of distribution, the measurement of "time to first recurrence" would be a valid statistical surrogate of the frequency of symptomatic episodes [3] . If the pattern of recurrences deviates, the error in using "time to first recurrence" to measure episode frequency increases dramatically. Its effect is a significant loss of statistical power and one would require parallel arm or crossover trials with much larger sample size to demonstrate treatment efficacy [4] .
There are several experimental studies that have attempted to evaluate if such episodes follow a Poisson process. In the original study from four patients with 12-14 consecutive symptomatic episodes of paroxysmal supraventricular tachycardia recorded by transtelephonic monitoring, it was observed that each patient's inter-episode intervals (measured from the termination of one episode to the onset of the next one) fit an exponential distribution i.e. a Poisson process [2] . These results were extended to paroxysmal AF by Greer et al., who observed that in 6 out of 8 patients, the inter-episode intervals also followed a Poisson process [6] . The other two patients had significant deviations. This was followed by a study by Rose et al. who evaluated the distribution of the time of onset of paroxysmal atrial tachyarrhythmia episodes from 30 patients with implanted pacemakers that store episode information [3] . They suggested that the Weibull distribution might provide a better fit than the Poisson model because the episodes clustered i.e. the risk of another episode was greatest after one had terminated and this risk declined over time. It is important to note that symptomatic as well as asymptomatic episodes were included in this and all subsequent publications utilizing data from implantable devices that monitor atrial tachyarrhythmia episodes. Studies with ambulatory recordings have shown that asymptomatic atrial fibrillation and supraventricular tachycardia episodes are approximately 12 times more frequent than symptomatic episodes [7] although it is not known whether the symptomatic episodes are randomly distributed among all the atrial tachyarrhythmia episodes. Kaemmerer et al. [4] also evaluated the distribution of inter-episode time intervals of atrial tachyarrhythmias episodes derived from the data stored in the implanted defibrillator in 14 patients. All episodes were carefully reviewed. He concluded that there was significant clustering of atrial tachyarrhythmia episodes and in 13 of the 14 patients; the fit to an exponential distribution was rejected. In contrast, data from 5 of 14 patients did fit a Weibull distribution (Figure 2 ). Using Monte Carlo methods, it was demonstrated that deviation from the exponential Poisson distribution results in a significant increase in number of patients required to demonstrate efficacy of a therapy with either parallel and crossover study designs. Recently, Shehadeh et al. [5] also studied the temporal patterns of the onset of atrial tachyarrhythmia recurrence in patients following implantation of a dual chamber ICD,
